Dexcel Drug Patent Portfolio
Dexcel owns 4 orange book drugs protected by 6 US patents Given below is the list of Dexcel's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10537585 | Compositions comprising dexamethasone | 18 Dec, 2037 | Active |
| US11304961 | Compositions comprising dexamethasone | 18 Dec, 2037 | Active |
| US10076494 | Stable orally disintegrating pharmaceutical compositions | 08 Dec, 2036 | Active |
| US10835488 | Stable orally disintegrating pharmaceutical compositions | 08 Dec, 2036 | Active |
| US11077055 | Orally disintegrating compositions | 21 Apr, 2036 | Active |
| US11986554 | Orally disintegrating compositions | 21 Apr, 2036 | Active |
Latest Legal Activities on Dexcel's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Dexcel.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 May, 2024 | US10835488 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 May, 2024 | US10835488 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Jul, 2023 | US10537585 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Oct, 2022 | US9023391 (Litigated) |
|
Recordation of Patent Grant Mailed
Critical
| 19 Apr, 2022 | US11304961 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 19 Apr, 2022 | US11304961 |
|
Email Notification
Critical
| 31 Mar, 2022 | US11304961 |
|
Issue Notification Mailed
Critical
| 30 Mar, 2022 | US11304961 |
|
Application Is Considered Ready for Issue
Critical
| 28 Mar, 2022 | US11304961 |
| Dispatch to FDC | 28 Mar, 2022 | US11304961 |
|
Issue Fee Payment Verified
Critical
| 07 Mar, 2022 | US11304961 |
|
Issue Fee Payment Received
Critical
| 07 Mar, 2022 | US11304961 |
|
Electronic Review
Critical
| 02 Mar, 2022 | US11304961 |
|
Email Notification
Critical
| 02 Mar, 2022 | US11304961 |
|
Mail Notice of Allowance
Critical
| 02 Mar, 2022 | US11304961 |
Dexcel's Family Patents
Recent FDA approvals and tentative approvals for Dexcel
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Tofacitinib Citrate |
ORIG-2
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 16 Dec, 2024 |
Dexcel Drug List
Given below is the complete list of Dexcel's drugs and the patents protecting them.
1. Esomeprazole Magnesium
Esomeprazole Magnesium is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10076494 | Stable orally disintegrating pharmaceutical compositions |
08 Dec, 2036
(10 years from now)
| Active |
| US10835488 | Stable orally disintegrating pharmaceutical compositions |
08 Dec, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Esomeprazole Magnesium's drug page
2. Hemady
Hemady is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10537585 | Compositions comprising dexamethasone |
18 Dec, 2037
(11 years from now)
| Active |
| US11304961 | Compositions comprising dexamethasone |
18 Dec, 2037
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hemady's drug page
3. Lansoprazole
Lansoprazole is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11077055 | Orally disintegrating compositions |
21 Apr, 2036
(10 years from now)
| Active |
| US11986554 | Orally disintegrating compositions |
21 Apr, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lansoprazole's drug page
4. Omeprazole
Omeprazole is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10076494 | Stable orally disintegrating pharmaceutical compositions |
08 Dec, 2036
(10 years from now)
| Active |
| US10835488 | Stable orally disintegrating pharmaceutical compositions |
08 Dec, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Omeprazole's drug page